Stock comparison
Alvotech
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 79B | HALO |
| Benjamin Graham | 51D | 83A | HALO |
| Philip Fisher | 55C | 65B | HALO |
| Peter Lynch | 78C | 53D | ALVO |
| Joel Greenblatt | 45D | 40D | ALVO |
| Charlie Munger | 52D | 80C | HALO |
| Terry Smith | 43D | 84A | HALO |
Side-by-side metrics
| Metric | ALVO | HALO |
|---|---|---|
| Market cap | $1.04B | $8.1B |
| P/E (TTM) | 33.1x | 24.0x |
| EV/EBIT | 29.5x | 10.2x |
| ROIC (TTM) | 1.3% | 23.65% |
| Gross margin | 59.82% | 81.24% |
| Net margin | 4.76% | 23.13% |
| Revenue CAGR 5y | 99.83% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | - | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Debt / Equity-vs 1.0x+119%
- Revenue CAGR 5y99.83%vs 33.23%+67%
HALO leads on
- ROIC (TTM)23.65%vs 1.3%+95%
- Market cap$8.1Bvs $1.04B+87%
- Net margin23.13%vs 4.76%+79%
- EV/EBIT10.2xvs 29.5x+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.